Completion Characteristics of Non-Hispanic Blacks with Tuberculosis and HIV

• Main Author: Green, Vernard Darrell
• Format: Others
• Language: en
• Published: ScholarWorks 2017
• Subjects: co-infection; co-morbidity; Completion of Therapy; HIV & TB; RVCT; Tuberculosis; Epidemiology; Medicine and Health Sciences; Public Health Education and Promotion
• Online Access: https://scholarworks.waldenu.edu/dissertations/6568; https://scholarworks.waldenu.edu/cgi/viewcontent.cgi?article=7847&context=dissertations

Tuberculosis (TB) and human immunodeficiency virus (HIV) are difficult conditions to manage, in tandem they pose even more challenges to public health programs in identifying coinfection to ensure that all TB cases are treated to completion of therapy (COT). The purpose of this study was to test variables that predicted COT among the HIV/TB coinfected population of non-Hispanic, U.S.-born Blacks alive at the time of diagnosis. Social determinants of health were the theoretical foundation used to guide the study based on data from the Report of Verified Cases of TB (RVCT) between 2009 and 2014. Relationships were tested between ethnic/racial group membership and the likelihood of COT, and whether any association to COT was moderated by COT eligibility; a Centers for Disease Control and Prevention calculated algorithm considering disease severity, site, age, and disease complexity. The research design was a longitudinal quantitative approach using binary logistic regression to identify correlated variables associated with COT in the final model. The results showed no statistically significant differences among racial/ethnic groups, age, and gender for COT. COT was moderated by COT eligibility; odds ratio (5.4 - 11.6) times more likely to complete therapy. This study supports positive social change for programs by providing data driven outcomes to providers that support outreach, patient education, and disease prevention. In addition, this research describes an evaluation metric based on performance to set a foundation for collaboration among partners who manage other comorbidities in the United States.